Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0N9GH
|
|||
| Drug Name |
PMID28454500-Compound-9
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
REATA PHARMACEUTICALS, INC. ANDERSON, Eric JIANG, Xin VISNICK, Melean BENDER, Christopher, F. LIU, Xiaofeng
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C30H41NO3
|
|||
| Canonical SMILES |
CC1C2CCC3(C(=CC(=O)C4C3(CCC5(C4CC(CC5)(C)C)CO)C)C2(C=C(C1=O)C#N)C)C
|
|||
| InChI |
1S/C30H41NO3/c1-18-20-7-8-28(5)23(27(20,4)14-19(16-31)25(18)34)13-22(33)24-21-15-26(2,3)9-11-30(21,17-32)12-10-29(24,28)6/h13-14,18,20-21,24,32H,7-12,15,17H2,1-6H3/t18-,20-,21?,24?,27-,28+,29+,30+/m0/s1
|
|||
| InChIKey |
UHGNLMUWOYPXQG-WDPAWIMBSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cysteines of Keap1 (KEAP1 Cysteines) | Target Info | Modulator | [1] |
| Nuclear factor erythroid 2-related factor 2 (Nrf2) | Target Info | Activator | [1] | |
| Target's Patent Info | Cysteines of Keap1 (KEAP1 Cysteines) | Target's Patent Info | [1] | |
| Nuclear factor erythroid 2-related factor 2 (Nrf2) | Target's Patent Info | [1] | ||
| KEGG Pathway | Protein processing in endoplasmic reticulum | |||
| NetPath Pathway | IL5 Signaling Pathway | |||
| WikiPathways | Oxidative Stress | |||
| Transcriptional activation by NRF2 | ||||
| NRF2 pathway | ||||
| Nuclear Receptors Meta-Pathway | ||||
| Aryl Hydrocarbon Receptor Pathway | ||||
| Mesodermal Commitment Pathway | ||||
| Aryl Hydrocarbon Receptor | ||||
| Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | ||||
| Arylhydrocarbon receptor (AhR) signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.